China's National Medical Products Administration (NMPA) approved NEO — a coin-sized invasive brain-computer interface from Neuracle Technology and Tsinghua University researchers — for commercial use beyond clinical trials, making it the world's first invasive BCI cleared for sale, according to MIT Technology Review, Scientific American, and People's Daily reporting on the March 2026 decision that resurfaced globally in June 2026. Neuralink, by contrast, remains in FDA-supervised human trials with 21 participants as of early 2026 — no US commercial approval yet. What NEO Is — and Why Regulators Moved Faster NEO is an epidural implant: eight sensors sit on the dura mater (the brain's protective membrane), not inside the cortex like Neuralink's N1 threads. Design choice NEO (Neuracle) Neuralink N1 Placement On dura mater — ~90 min surgery Penetrates cortex Risk profile Lower hemorrhage / glial scarring risk Higher invasiveness, signal degradation over time Output Brain signals → skull transmitter → PC → soft robotic glove Direct neural read/write for cursor/device control Approval NMPA commercial (March 2026) Clinical trials only (US) Avinash Singh (University of Technology Sydney), cited by MIT Technology Review, said the epidural path faces fewer regulatory constraints than penetrating designs — a plausible reason NEO reached market first despite Neuralink's global headlines. Clinical Numbers — Not Just a Press Release Per NMPA and Neuracle statements reported by Xinhua / People's Daily: 36 clinical procedures since October 2023 4 feasibility trials + 32 multi-center GCP trials (most in 2025) Patients showed varying grasp improvement; some neural remodeling signs Approved cohort: ages 18–60, limb paralysis from spinal cord injury, some residual arm function Dong Hui, 39, paralyzed after a car accident, told MIT Technology Review he wrote his name again after 11 months of ~2.5-hour daily training — grabbing a ball on day nine without the glove was a breakthrough moment. Our Analysis: Why Developers and Infra Teams Should Care This is not sci-fi cosplay — it is medical device manufacturing + signal processing + rehab software at national scale. 1. China just created a commercial BCI category Days after approval, China assigned NEO a health-insurance product code — the first step toward partial reimbursement in the state healthcare system. That is volume manufacturing, not lab demos — same pattern as China GPU/robotics five-year plan priorities. 2. 'Race' framing is wrong — market definitions differ Meicen Sun (University of Illinois), cited by MIT Technology Review: US wins on state-of-the-art performance; China wins on accessible scale. Nick Ramsey (Radboud University) warns against a simplistic US-China 'endpoint' race — BCIs have no finish line yet. 3. Neuralink's consumer fantasy vs hospital reality Musk has discussed healthy humans getting implants someday. NEO's approved label is spinal cord injury patients with specific arm function — hospital rollouts, not phone-adjacent consumer electronics. 4. Pipeline behind NEO Beinao-1 (NeuCyber NeuroTech / Beijing brain institute) targets movement + speech for SCI and ALS — possible approval ~2028 per expert commentary. NeuroXess, StairMed, and others already in field trials. 5. Rare US-China collaboration lane Axoft (Cambridge, MA) reportedly partners with a Shanghai hospital on BCI trials — neurotech is one of few sectors still doing cross-border human studies despite export tensions. Developer angle: BCI stacks need low-latency signal decoding, on-device inference, rehab gamification, and HIPAA-grade logging — same talent pool as embodied AI / humanoid robots and Nvidia physical AI. Key Takeaways March 2026 (NMPA): NEO = world's first invasive BCI approved for commercial sale beyond trials Neuracle + Tsinghua — coin-sized epidural implant on dura mater, not deep cortex penetration 36 trials since Oct 2023; patient Dong Hui regained writing after 11 months training Neuralink: 21 trial users, no US commercial approval; N1 penetrates cortex China policy: BCI listed in latest five-year plan alongside quantum + humanoids; insurance coding started For developers: commercial BCIs = medical software + signal ML + rehab UX — new regulated hardware category What to watch: Beinao-1 (~2028), US FDA path for Neuralink, cross-border trials like Axoft-Shanghai

Source: abhs.in

Read Original Source →